Genmab makes duobody deal with Novo Nordisk

Genmab makes duobody deal with Novo Nordisk

Company Announcement Two commercial DuoBody® technology licenses granted to Novo Nordisk Genmab receives USD 2 million upfront payment Copenhagen, Denmark; August 14, 2015 — Genmab A/S (OMX: GEN) announced today it has entered an agreement to grant Novo Nordisk commercial licenses to use the DuoBody technology platform to create and develop  bispecific antibody candidates for two therapeutic programs.  The bispecific …

Read more.

---
Ventetoclax meets endpoint

Ventetoclax meets endpoint

Regulatory applications for venetoclax are planned for submission to the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) by the end of 2015 Venetoclax is a small molecule inhibitor of the BCL-2 protein, which potentially represents a new way of treating blood cancers South San Francisco, CA -- August 12, 2015 -- Genentech, a member of the …

Read more.

---
2015_outlook

Genmab - a pivotal year for the new strategy

Genmab is reporting the 11th august after close of the Danish market and that is traditionally a very quiet affair. With the company so close to a likely approval of cancer drug blockbuster, Daratumumab, it is fair to ask the question; will company succes on drug development equal more value for shareholders? The interest and dare I say hype for …

Read more.